

For Immediate Release
Alembic Pharmaceuticals Limited
Consolidated Results for Quarter/Year ended
31.03.2015

Editor's Synopsis

A) Quarter ended 31st March 2015

- **Successfully passed US FDA audit of formulation facility at Panelav without any 483 observations**
- **Successfully passed US FDA audit of Bio equivalence center without any 483 observations**
- **Net sales up by 9% to Rs 508.0 crores against Rs 465.2 crores**
- **Profit before tax up by 10% to Rs 88.5 crores against Rs 80.8 crores**
- **Net profit after tax up by 15% to Rs 70.3 crores against Rs 61.3 crores**

B) Year ended 31st March 2015

- **Net sales up by 11% to Rs 2067.7 crores against Rs 1868.4 crores**
- **Profit before tax up by 16% to Rs 359.1 crores against Rs 310.6 crores**
- **Net profit after tax up by 20% to Rs 282.9 crores against Rs 235.5 crores**
- **EBITDA margins at 19.6% at Rs 406.1 crores compared to 19.1% at Rs 357.7 crores**

C) Appointment of Mr. Pranav Amin and Mr. Shaunak Amin as Joint Managing Directors of the Company

Vadodara, 27th April, 2015

Alembic Pharmaceuticals Limited reported a 9% increase in revenues to Rs 508.0 crores for the quarter ended 31st March 2015, compared to Rs 465.2 crores in the corresponding quarter last year.

The Company posted 10% growth in profit before tax at Rs 88.5 crores for the quarter ended 31st March 2015 against Rs 80.8 crores posted in the corresponding quarter last year.

The net profit grew by 15% at Rs 70.3 crores for the quarter ended 31st March 2015 against Rs 61.3 crores in the corresponding quarter last year.

The company reported 11% increase in revenue for year ended 31st March 2015 to Rs 2067.7 crores against Rs 1868.4 crores in the last year.

The Company reported 16% growth in profit before tax at Rs. 359.1 crores for Year ended 31st March 2015 against Rs. 310.6 crores in the last year. The company also reported 20% growth in net profit for year ended 31st March 2015 Rs 282.9 crores against Rs 235.5 crores in the last year.

Mr. Pranav Amin and Mr. Shaunak Amin were earlier designated as Director & President – International Business and Director & President – Branded Formulations Business respectively. The Company has made significant growth under their leadership and considering their roles and responsibilities, are being re-designated as Joint Managing Directors of the Company with effect from 27th April 2015.

Dividend

The Board has recommended dividend on equity shares at Rs 3.50 per share i.e. 175% for 14-15 (P.Y. Rs 3.00 per share i.e. 150%)

India Branded Formulations Business

The India Branded formulations business grew by 16% to Rs 232.1 crores in the quarter against Rs 199.4 crores over the corresponding quarter of the previous year.

The India Branded formulations business posted sales for year ended 31st March 2015 of Rs 980.8 crores against Rs 850.6 crores with 15% growth over the previous year.

Specialty and Acute segments grew by 22% and 11% respectively in current quarter. For the year the growth are 21% and 9% respectively for Specialty and Acute segments.

International Generics

International Generic Formulation grew by 8% to Rs 147.9 crores in the quarter against Rs 136.6 crores over the corresponding quarter of the previous year.

International Generic Formulation posted sales for the year ended 31st March 2015 of Rs 518.5 crores against Rs 468.4 crores with 11% growth over the previous year.

2 ANDA applications were filed during the quarter, 7 ANDA applications for the year ended 31st March 2015, taking cumulative ANDA/NDA filings of the Company to 68. During the quarter 1 ANDA approval was received, 5 ANDA approvals for the year ended 31st March 2015, taking cumulative ANDA/NDA approvals to 37 (including 4 tentative approvals).

2 DMF applications were filed during the quarter, 6 DMF applications for the year ended 31st March 2015, taking cumulative DMF filings of the Company to 72.

Summary of Total Revenue is as under:

(Rs in Lacs)						
Particulars	Q4 FY15	Q4 FY14	% Change	FY 14-15	FY 13-14	% Change
Formulation						
India Branded	23208	19945	16%	98084	85064	15%
India Generics	3209	2867	12%	12274	12071	2%
International Branded	903	1759	(-)49%	6349	7360	(-)14%
International Generics	14788	13665	8%	51845	46837	11%
API	8524	8098	5%	36650	33885	8%
Export Incentives	163	188	-	1571	1624	-
Total	50795	46522	9%	206773	186841	11%

The Profit break-up is as under:

(Rs in Lacs)						
Particulars	Q4 FY15	Q4 FY14	% Change	FY 14-15	FY 13-14	% Change
EBITDA	9866	9129	8%	40607	35771	14%
Profit Before Tax	8848	8078	10%	35908	31060	16%
Net Profit after Tax	7033	6129	15%	28293	23550	20%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Alembic Pharmaceuticals Limited

Ajay Kumar Desai

Phone: +91 22 – 306 11681

Email: ajay.desai@alembic.co.in

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in